Renal manifestations of hepatitis C infection (Q33586586)

28 July 2017

1 reference

title

Renal manifestations of hepatitis C infection (English)

1 reference

28 July 2017

1 reference

Daghestani L

1

1 reference

PubMed ID

10190385

28 July 2017

Pomeroy C

series ordinal

2

1 reference

PubMed ID

10190385

28 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

American Journal of Medicine

28 July 2017

1 reference

28 July 2017

106

1 reference

28 July 2017

3

1 reference

28 July 2017

347-354

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

28 July 2017

1 reference

Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Renal manifestations of hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Mother-to-infant transmission of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

HCV genotypes in chronic hepatitis C and response to interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Predictive factors of a response to interferon therapy in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Cytotoxic T cells and viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Renal involvement in essential mixed cryoglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Mixed cryoglobulinemia and hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Membranoproliferative glomerulonephritis and hepatitis C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Hepatitis C virus infection and membranous glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Diffuse proliferative glomerulonephritis with hepatitis C virus-like particles in paramesangial dense deposits in a patient with chronic hepatitis C virus hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Membranous glomerulonephritis in association with hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Hepatitis C infection and membranoproliferative glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Hepatitis C in chronic renal failure patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

High prevalence of hepatitis C virus antibody in patients with chronic renal failure at the start of hemodialysis therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Incidence and risk factors of hepatitis C virus infection in a haemodialysis unit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Hepatitis C in dialysis patients: relationship to blood transfusions, dialysis and liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Detection of hepatitis C infection by polymerase chain reaction among hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Membranoproliferative glomerulonephritis and hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Hepatitis C virus-associated glomerulonephritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Fibrillary glomerulonephritis associated with hepatitis C viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Searching for hepatitis C virus antibodies in chronic primary glomerular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Hepatitis C virus infection in patients with essential mixed cryoglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

A role for hepatitis C virus infection in type II cryoglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Hepatitis C virus and autoimmunity: Fortuitous association or reality?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Hepatitis C virus in renal tissue of patients with glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Detection of anti-hepatitis C virus antibodies in patients undergoing dialysis by utilizing a hepatitis C virus 3.0 assay: correlation with hepatitis C virus RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Membranoproliferative glomerulonephritis and hepatitis C: effects of interferon-alpha therapy on clinical outcome and histological pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

The treatment of chronic viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Interferon treatment for chronic hepatitis C virus infection in uremic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Nephrotic syndrome during treatment with interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Suicide associated with alfa-interferon therapy for chronic viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Autoimmune chronic hepatitis exacerbated by alpha-interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Ribavirin therapy for cryoglobulinemia and thrombocytopenia associated with hepatitis C virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Mixed cryoglobulinemia and membranoproliferative glomerulonephritis associated with hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Therapeutic approaches in mixed cryoglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Glomerulonephritis in renal allografts associated with hepatitis C infection: a possible relationship with transplant glomerulopathy in two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900014-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)00014-5

1 reference

28 July 2017

1 reference

PubMed ID

10190385